Universal flu vaccine BiondVax goes robustly beyond first phase II trial
This article was originally published in Scrip
Executive Summary
The prospects of a "universal" flu vaccine becoming a pharmaceutical reality have received a boost with positive results from the first Phase II trial of an investigational product from the Israeli biotech company BiondVax Pharmaceuticals.
You may also be interested in...
Novartis Close To EU Approval For Zolgensma At Last
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
mRNA Vaccines – A Novel Weapon Against Coronavirus
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
CureVac Denies Takeover Reports As It Slates Phase I Coronavirus Vaccine Study For Early Summer
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.
Need a specific report? 1000+ reports available
Buy Reports